文献速递呼吸危重症与机械通气呼吸道感染

机械通气非COVID-19与COVID-19肺炎患者活化中性粒细胞释放蛋白酶的研究

Proteinase release from activated neutrophils in mechanically ventilated patients with non-COVID-19 and COVID-19 pneumonia.
PubMed 文献 · Eur Respir J · 2021-04-29

该研究对比机械通气的非COVID-19与COVID-19肺炎患者,发现COVID-19 ARDS患者气道和血液中可释放生物活性中性粒细胞弹性蛋白酶相关蛋白酶,水平与非COVID ARDS相当。中性粒细胞丝氨酸蛋白酶(NSPs)包括弹性蛋白酶(NE)、蛋白酶3(PR3)和组织蛋白酶G(CatG),在ARDS病理生理中起作用,可能成为治疗干预靶点。

要点

  • COVID-19 ARDS患者气道和血液中中性粒细胞弹性蛋白酶相关蛋白酶释放水平与非COVID ARDS相当。
  • 中性粒细胞丝氨酸蛋白酶(NE、PR3、CatG)参与ARDS病理生理,是潜在治疗靶点。
  • 重症肺炎常并发ARDS,死亡率约40%。

核心结论

  • COVID-19 ARDS与中性粒细胞弹性蛋白酶相关蛋白酶释放至气道和血液有关,水平与非COVID ARDS相当。

研究设计与样本

  • 研究对比机械通气的非COVID-19与COVID-19肺炎患者。

主要发现

  • COVID-19 ARDS患者气道和血液中可释放生物活性中性粒细胞弹性蛋白酶相关蛋白酶,水平与非COVID ARDS相当。
  • 中性粒细胞丝氨酸蛋白酶(NSPs)包括弹性蛋白酶(NE)、蛋白酶3(PR3)和组织蛋白酶G(CatG),从活化细胞释放,参与ARDS病理生理。
  • NSPs在骨髓中性粒细胞前体中合成,经组织蛋白酶C(CatC)转化为活性形式,储存于胞质颗粒,刺激后分泌至细胞外。

关键数值与推荐

  • 重症肺炎常伴ARDS,死亡率约40%。

临床怎么用

  • NSPs可能成为肺炎诱导ARDS的未开发治疗干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

COVID-19 ARDS is associated with release of biologically active neutrophil elastase-related proteinases to the airways and blood at a comparable level to non-COVID ARDS https://bit.ly/3nihveh Severe cases of pneumonia are frequently associated with acute respiratory distress syndrome (ARDS), which carries a mortality rate of about 40% [1]. Uncontrolled host inflammatory response in the lung is a key factor in the transition from pneumonia to ARDS, with alveolocapillary membrane disruption leading to interstitial and alveolar oedema [2]. Neutrophils are part of the innate immune system and are the first responders to local tissue damage and infection. Recruited neutrophils are considered important actors in lung tissue injury [3]. Indeed, their broad arsenal of antimicrobial weaponry can cause direct and indirect collateral damage. Neutrophil serine proteinases (NSPs), including elastase (NE), proteinase 3 (PR3) and cathepsin G (CatG), are released from activated cells and play a part in ARDS pathophysiology, as illustrated in both preclinical and clinical studies [4]. Thus, NSPs emerge as an untapped point for therapeutic interventions in pneumonia-induced ARDS [4]. These NSPs are readily synthesised in neutrophil precursors within the bone marrow and are converted into their active form by cathepsin C (CatC) [5]. They are stored together in cytoplasmic granules and secreted into the extracellular compartment upon stimulation [6].

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Seren S, Derian L, Keleş I, et al. Proteinase release from activated neutrophils in mechanically ventilated patients with non-COVID-19 and COVID-19 pneumonia. Eur Respir J. 2021. PMID: 33419887. doi:10.1183/13993003.03755-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。